Core Insights - EyePoint Pharmaceuticals, Inc. is focused on developing innovative therapeutics for serious retinal diseases, with a commitment to improving patient lives [3][4] - The company will participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025 [1] Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company with a lead product candidate, DURAVYU, which is a sustained delivery treatment for VEGF-mediated retinal diseases [3] - DURAVYU combines vorolanib, a selective tyrosine kinase inhibitor, with next-generation bioerodible Durasert E technology [3] - The company is currently evaluating DURAVYU in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD), with topline data expected in 2026 [3] - DURAVYU has also completed a positive Phase 2 clinical trial in diabetic macular edema (DME), with Phase 3 planning underway [3] - Despite existing therapies, patients with wet AMD and DME continue to experience long-term vision loss, with wet AMD being the leading cause of vision loss in individuals aged 50 and older in the U.S. [3] Product and Development - Vorolanib is exclusively licensed to EyePoint for the localized treatment of all ophthalmic diseases outside of specific regions in Asia [5] - DURAVYU has been conditionally accepted by the FDA as the proprietary name for EYP-1901, although it has not yet received FDA approval [5]